EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research

Meichen Pan iD, Zhongliang Fu, Hongwei Hou, Chunrong Yang, Jinghong Li iD

Small Methods · 2025

DOI: 10.1002/smtd.202500402 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Small Methods, 2025. Verfasst von Meichen Pan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Life Science Academy, Beijing, 102209, China. Hauptthemen laut MEDLINE: Proteolysis, Ubiquitin-Protein Ligases, Drug Discovery. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 154 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis‐targeting chimera (PROTAC) technology is a revolutionary tool for drug discovery that simultaneously recruits E3 ligase and the protein of interest to induce ubiquitination and subsequent proteasomal degradation. Since the inaugural PROTAC prototype emerged in 2001, this modality has garnered significant interest across academia and industry, catalyzing transformative applications in drug discovery and chemical biology. The field has evolved from foundational investigations into molecular design, structural optimization, and protein target extension to address more sophisticated challenges, such as structural analysis of ternary complexes, expansion of diversified therapeutic indications, and clinical translation studies. Recent progress across chemical, pharmaceutical, and biochemical sciences has reshaped PROTAC design paradigms, which in turn expanded the chemical biology toolkit. In this review, pivotal milestones are systematically chronicled in PROTAC development, evaluate emerging strategies for diversifying E3 ligase utilization and expanding the scope of degradable targets, and summarize a series of instrumental and biochemical methodologies that propelled sequential breakthroughs. Additionally, forward‐looking trajectories are proposed to address current limitations and accelerate the clinical maturation of PROTAC‐based therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisUbiquitin-Protein LigasesDrug DiscoveryHumansUbiquitinationProteasome Endopeptidase ComplexAnimals

Stichwörter der Autor:innen

PROTACbiochemical methodsdrug discoverytargeted protein degradation

Substanzen

Ubiquitin-Protein LigasesProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Beijing Life Science Academy, Beijing, 102209, China.
  • School of Biomedical Sciences, Hunan University, Changsha, Hunan, 410082, China.
  • New Cornerstone Science Laboratory, Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing, 100084, China.
  • Center for Bioanalytical Chemistry, Hefei National Laboratory of Physical Science at Microscale, University of Science and Technology of China, Hefei, 230026, China.

ORCID-Profile: Meichen Pan, Jinghong Li

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Pan, M., Fu, Z., Hou, H., Yang, C., & Li, J. (2025). Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research. Small Methods. https://doi.org/10.1002/smtd.202500402

Vancouver

Pan M, Fu Z, Hou H, Yang C, Li J. Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research. Small Methods. 2025. doi:10.1002/smtd.202500402

BibTeX
@article{Pan2025,
  author = {Pan, Meichen and Fu, Zhongliang and Hou, Hongwei and Yang, Chunrong and Li, Jinghong},
  title = {Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research},
  journal = {Small Methods},
  year = {2025},
  doi = {10.1002/smtd.202500402}
}
Kostenlos starten →